 Pregnant women will be enrolled in the registry prospectively after exposure to QIV in routine clinical settings but before knowledge of the pregnancy outcome. Women exposed to QIV with or without adverse events will be recorded in the Global Pharmacovigilance Database and medically reviewed. Pregnancy outcomes will be sought via questionnaires sent to the reporter at enrollment, estimated time of delivery, and six months after delivery. Descriptive statistical methods will be the primary approach for summarizing data. 